📊 OSTX Key Takeaways
Is OS Therapies Inc (OSTX) a Good Investment?
OS Therapies faces imminent financial distress with negative stockholders equity of -$10.8M and liabilities exceeding assets by $9.8M, indicating technical insolvency. The company has critical liquidity crisis with current ratio of 0.05x and only $917.6K cash against -$5.0M free cash flow, providing less than two months of runway without financing. With no reported revenue and sustained operating losses, the company requires immediate capital infusion for survival.
OSTX is pre-revenue with severe liquidity stress, negative equity, and sustained operating losses, indicating high going‑concern risk absent immediate external funding. While capex is low and EPS loss narrowed YoY, the balance sheet and cash runway are critically weak, making dilution or unfavorable financing highly likely.
OS Therapies Inc Key Strengths (OSTX)
- YoY improvement in diluted EPS loss (23.4%) suggests cost management progress
- Minimal asset base consistent with early-stage biotech R&D focus
- Company remains operationally active despite severe financial constraints
- Low capital intensity supports R&D focus (minimal capex)
- EPS loss narrowed YoY, indicating some discipline
- Public listing may enable access to capital markets
OSTX Stock Risks: OS Therapies Inc Investment Risks
- Negative stockholders equity of -$10.8M indicates technical insolvency on accounting basis
- Critical liquidity crisis: current and quick ratios of 0.05x signal inability to meet near-term obligations
- Estimated cash runway under two months at current burn rate creates existential funding risk
- Liabilities of $17.1M exceed total assets of $7.3M by $9.8M
- Negative operating cash flow of -$4.6M and negative free cash flow of -$5.0M unsustainable
- Pre-revenue or minimal revenue status with no clear path to profitability
- Zero insider Form 4 activity in last 90 days suggests potential loss of confidence
- Going‑concern risk: cash $270k, current ratio 0.03x, negative equity
- Persistent heavy cash burn and losses (OCF -$14.24M; FCF -$14.70M)
- High financing/dilution risk and weak interest coverage (-34.6x)
Key Metrics to Watch
- Cash position and months of runway remaining before depletion
- Announcement of financing or capital raise and dilution impact
- Operating burn rate trajectory and cost reduction initiatives
- Revenue recognition timeline and commercial milestone achievement
- Balance sheet restructuring or debt forbearance agreements
- Cash & equivalents vs. quarterly operating cash burn
- Regulatory/clinical milestones leading to partnerships or revenue
OS Therapies Inc (OSTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
OSTX Profit Margin, ROE & Profitability Analysis
OSTX vs Healthcare Sector: How OS Therapies Inc Compares
How OS Therapies Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is OS Therapies Inc Stock Overvalued? OSTX Valuation Analysis 2026
Based on fundamental analysis, OS Therapies Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
OS Therapies Inc Balance Sheet: OSTX Debt, Cash & Liquidity
OSTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: OS Therapies Inc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.28 indicates the company is currently unprofitable.
OSTX Revenue Growth, EPS Growth & YoY Performance
OS Therapies Inc Dividends, Buybacks & Capital Allocation
OSTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for OS Therapies Inc (CIK: 0001795091)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OSTX
What is the AI rating for OSTX?
OS Therapies Inc (OSTX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OSTX's key strengths?
Claude: YoY improvement in diluted EPS loss (23.4%) suggests cost management progress. Minimal asset base consistent with early-stage biotech R&D focus. ChatGPT: Low capital intensity supports R&D focus (minimal capex). EPS loss narrowed YoY, indicating some discipline.
What are the risks of investing in OSTX?
Claude: Negative stockholders equity of -$10.8M indicates technical insolvency on accounting basis. Critical liquidity crisis: current and quick ratios of 0.05x signal inability to meet near-term obligations. ChatGPT: Going‑concern risk: cash $270k, current ratio 0.03x, negative equity. Persistent heavy cash burn and losses (OCF -$14.24M; FCF -$14.70M).
What is OSTX's revenue and growth?
OS Therapies Inc reported revenue of N/A.
Does OSTX pay dividends?
OS Therapies Inc does not currently pay dividends.
Where can I find OSTX SEC filings?
Official SEC filings for OS Therapies Inc (CIK: 0001795091) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OSTX's EPS?
OS Therapies Inc has a diluted EPS of $-0.27.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is OSTX's fundamental grade?
Based on our AI fundamental analysis in May 2026, OS Therapies Inc has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is OSTX stock overvalued or undervalued?
Valuation metrics for OSTX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is OSTX's AI grade for 2026?
Our dual AI analysis gives OS Therapies Inc a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OSTX's free cash flow?
OS Therapies Inc's operating cash flow is $-4.6M, with capital expenditures of $466.4K.
How does OSTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.05 (avg: 2).